EMA Recommends Extending Indications for Durvalumab By Ogkologos - July 17, 2025 551 0 Facebook Twitter Google+ Pinterest WhatsApp New indication concerns a neoadjuvant and adjuvant treatment of patients with muscle invasive bladder cancer Source RELATED ARTICLESMORE FROM AUTHOR Lisocabtagene Maraleucel Shows Deep, Durable Responses in Patients with Relapsed or Refractory MZL After at Least Two Previous Lines of Systemic Therapy FDA Updates Safety Labelling for Capecitabine and 5-FU on Risks Associated with DPD Deficiency Ultra-Low-Dose Nivolumab Significantly Improves OS Over Chemotherapy in Pretreated Patients with Solid Tumours MOST POPULAR GD2-CART01 May Induce Sustained Antitumour Effect in a Proportion of Patients... April 13, 2023 FDA Approves Pembrolizumab for Adjuvant Treatment of Stage IIB or IIC... December 7, 2021 How to Safely Keep Up With Your Cancer Screening and Care... December 10, 2020 Limited Efficacy of Nivolumab plus Ipilimumab in Adenoid Cystic Carcinomas, but... September 11, 2023 Load more HOT NEWS A Vaccine to Treat Non-Hodgkin Lymphoma Advancing in Clinical Trials Short-Term Radiotherapy with Preoperative Chemotherapy Followed by Surgery is Efficacious with... Ovarian Cancer Studies Aim to Reduce Racial Disparities, Improve Outcomes Breast Cancer Survivor Says Mistletoe Injections Have Kept Her Cancer-Free For...
